Gilead Sciences Inc (BUE:GILD)
ARS 26600 125 (0.47%) Market Cap: 111.51 Tn Enterprise Value: 131.94 Tn PE Ratio: 110.08 PB Ratio: 6.15 GF Score: 52/100

Gilead Sciences Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 01, 2021 / 05:30PM GMT
Release Date Price: ARS2721 (-2.63%)
Michael Jonathan Yee
Jefferies LLC, Research Division - Equity Analyst

All right. Well, good afternoon, everyone, and thank you for joining me on this afternoon's session here today at the 2021 Jefferies Global Healthcare Conference. I'm really grateful to have with me Gilead, the Chairman of the Board and CEO, Dan O'Day; as well as the Chief Commercial Officer, Johanna Mercier. And there's plenty to talk about at Gilead.

Questions & Answers

Michael Jonathan Yee
Jefferies LLC, Research Division - Equity Analyst

And so first, I would just love to maybe just start high level with Dan and maybe talk about a question and a topic that investors have on their mind, which is the word growth. And I think it seems to me that people struggle with whether Gilead is a growth company or how growthy and the different levers, I think, people are, I think, perplexed by.

So maybe you could just make a comment about, excluding perhaps Veklury, is Gilead going to grow this year and in '22 and '23? And maybe just what are the key levers that will do that? So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot